| Literature DB >> 34696844 |
Patricia M Graves1, Hayley Joseph2, Shaun P Coutts3, Helen J Mayfield4, Fuatai Maiava5, Tile Ann Ah Leong-Lui5, Palanitina Tupuimatagi Toelupe5, Vailolo Toeaso Iosia5, Siatua Loau5, Paulo Pemita5, Take Naseri5, Robert Thomsen5, Alvaro Berg Soto6, Thomas R Burkot6, Peter Wood6, Wayne Melrose6, Padmasiri Aratchige7, Corinne Capuano7, Sung Hye Kim7, Masayo Ozaki7, Aya Yajima8, Patrick J Lammie9, Eric Ottesen9, Lepaitai Hansell10, Rasul Baghirov10, Colleen L Lau11, Kazuyo Ichimori6.
Abstract
Lymphatic filariasis (LF) is a major public health problem globally and in the Pacific Region. The Global Programme to Eliminate LF has made great progress but LF is persistent and resurgent in some Pacific countries and territories. Samoa remains endemic for LF despite elimination efforts through multiple two-drug mass drug administrations (MDA) since 1965, including renewed elimination efforts started in 1999 under the Pacific Programme for Elimination of LF (PacELF). Despite eight rounds of national and two rounds of subnational MDA under PacELF, Samoa failed transmission assessment surveys (TAS) in all three evaluation units in 2017. In 2018, Samoa was the first to distribute countrywide triple-drug MDA using ivermectin, diethylcarbamazine (DEC), and albendazole. This paper provides a review of MDAs and historical survey results from 1998 to 2017 in Samoa and highlights lessons learnt from LF elimination efforts, including challenges and potential ways to overcome them to successfully achieve elimination.Entities:
Keywords: Aedes; Elimination; Lymphatic filariasis; PacELF; Samoa; Vector; W. bancrofti
Mesh:
Substances:
Year: 2021 PMID: 34696844 DOI: 10.1016/bs.apar.2021.03.002
Source DB: PubMed Journal: Adv Parasitol ISSN: 0065-308X Impact factor: 3.870